Randomised trial of pivampicillin plus pivmecillinam vs. pivampicillin in children and young adults with chronic obstructive pulmonary disease and infection with haemophilus influenzae

Current Medical Research and Opinion

Volumn 15, Issue 4, 1999, Pages 300-309

  Johansen, Helle Krogh ^b   Børch, Klaus ^c   Espersen, Frank ^a   Koch, Christian ^c   Høiby, Niels ^c  

^a STATENS SERUM INSTITUT   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c NONE

Author keywords

Chronic obstructive pulmonary disease; Haemophilus influenzae; Pivmecillinam plus pivampicillin; Randomised clinical trials

Indexed keywords

MIRAXID; PIVAMPICILLIN;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; ARTICLE; BACTERIAL INFECTION; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; REINFECTION;

EID: 0033430243     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007999909116501     Document Type: Article

References (21)

1. Foxwell, A. R., Kyd, J. M. and Cripps, A. W. (1998). Nontypable Haemophilus influenzae: pathogenesis and prevention. Microbiol. Molecular Biol. Rev., 62, 294-308.
2. Pressler, T., Szaff, M. and Høiby, N. (1984). Antibiotic treatment of Haemophilus influenzae and Haemophilus parainfluenzae infections in patients with cystic fibrosis. Acta Paediatr. Scand., 73, 541-547.
3. Bilton, D., Pye, A., Johnson, M. M., Mitchell, J. L., Dodd, M., Webb, A. K., Stockley, R. A. and Hill, S. L. (1995) The isolation and characterization of non-typeable Haemophilus influenzae from sputum of adult cystic fibrosis patients. Eur. Respir. J., 8, 948-953.
4. Campos, J., Román, F., Georgiou, M., García, C., Gómez-Lus, R., Cantón, R., Escobar, H. and Barquero, F. (1996). Long-term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis. J. Infect. Dis., 174, 1345-1347.
5. Høiby, N. (1995). Microbiology of cystic fibrosis. In: Hodson, M. E. and Geddes, D. M. (Eds.): Cystic Fibrosis. Chapman & Hall Medical, pp. 75-98.
6. Mearns, M. B. (1993). Cystic fibrosis: the first 50 years. A review of the clinical problems and their management. In: Dodge, J. A., Brock, D. J. H. and Widdicombe, J. H. (Eds.): Cystic Fibrosis - Current Topics. Wiley, pp. 217-250.
7. Möller, L. V. M., Regelink, A. G., Grasselier, H., van Alphen, L. and Dankert, J. (1998). Antimicrobial susceptibility of Haemophilus influenzae in the respiratory tracts of patients with cystic fibrosis. Antimicrob. Agents Chemother., 42, 319-324.
8. Pedersen, M., Støvring, S., Mørkassel, E., Koch, C. and Høiby, N. (1986). A comparative study of amoxycillin and pivampicillin in persistent Haemophilus influenzae infection of the lower respiratory tract in children with chronic lung disease. Scand. J. infect. Dis., 18, 245-254.
9. Pressler, T., Pedersen, S. S., Christiansen, L., Szaff, M., Koch, C. and Høiby, N. (1986). Sultamicillin - a new antibiotic in treatment of persistent lower respiratory tract infection caused by Haemophilus influenzae. J. Antimicrob. Chemother., 17, 529-533.
10. Frederiksen, B., Lanng, S., Koch, C. and Høiby, N. (1996). Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr. Pulmonol., 21, 153-158.
11. Bukh, N. (1983). Double-blind comparison of pivmecillinam plus pivampicillin (Miraxid®) with pivampicillin alone in chronic bronchitis; a Danish multi-centre study. Pharmatherapeutica, 3, 422-428.
12. Lund, F., Roholt, K., Tybring, L. and Godtfredsen, W. O. (1976). Mecillinam and pivampicillin - new β-lactam antibiotics with high activity against Gram-negative bacilli. Chemotherapy, 5, 159-165.
13. Grunberg, E., Cleeland, R., Beslind, G. and DeLorenzo, W. F. (1976). In vivo synergy between 6β-amidinopenicillanic acid derivatives and other antibiotics. Antimocrob. Agents. Chemother., 9, 589-594.
14. Spino, M. (1991). Pharmacokinetics of drugs in cystic fibrosis. Clin. Rev. Allergy, 9, 169-201.
15. Touw, D. J., Vinks, A. A. T. M. M., Mouton, J. W. and Horrevorts, A. M. (1998). Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Clin. Pharmacokinet. 35, 437-459.
16. Weber, A., de Groot, R., Ramsey, B., Williams, J. W. and Smith, A. (1991). Probenecid pharmacokinetics in cystic fibrosis. Dev. Pharmacol. Ther., 16, 7-12.
17. Eliopoulos, G. M. and Moellering Jr, R. C. (1996). Antimicrobial combinations. In: Lorian, V. (Eds.): Antibiotics in Laboratory Medicine. Williams and Wilkins, Baltimore, 4th edn, pp. 350-396.
18. Kilian, M. A. (1976). Taxonomic study of the genus Haemophilus, with the proposal of new species. J. Gen. Microbiol., 93, 9-62 (thesis).
19. Pedersen, S S. (1992). Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis. APMIS, 100, 1-79 (thesis).
20. Jensen, T., Pedersen, S. S., Stafanger, G., Høiby, N., Koch, C. and Bondesson, G. (1988). Comparison of amoxycillin/clavulanate with amoxycillin in children and adults with chronic obstructive pulmonary disease and infection with Haemophilus influenzae. Scand. J. Infect. Dis., 20, 517-525.
21. Verhoef, J. (1991). Prevention of infection by Gram-negative microorganisms. Inf. Dis. Clin. North. Am., 5, 835-845.